Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report

Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report Tahereh Rostami , Neda Alijani , Azadeh Kiumarsi , Soroush Rad , Seied Amirhosein Mirhoseini , Mohammadreza Rostami , Amir Hesabi , Seyed Ali Mousavi , Seied Asadollah Mousavi Department of Pediatric Cell Therapy, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran; Department of Infectious Diseases, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran; Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

[1]  A. Dang,et al.  Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review , 2021, Drug Safety.

[2]  Á. Avezum,et al.  Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial , 2021, BMJ.

[3]  Xiaoping Zhou,et al.  Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions? , 2020, Proceedings of the National Academy of Sciences.

[4]  Eric A. Meyerowitz,et al.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.

[5]  X. Forns,et al.  Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy , 2020, Journal of viral hepatitis.

[6]  M. T. Islam.  Mutation in hprt1 Gene or HPRT Deficiency May be a Restricting Progeny of Favipiravir in Covid-19 , 2020 .

[7]  T. Rostami,et al.  Pediatric Hematopoietic Stem Cell Transplant in the COVID-19 Pandemic: The Problems We Faced and The Strategies We Adopted , 2020, Archives of Pediatric Infectious Diseases.

[8]  P. Jacobson,et al.  Pharmacogenomics of COVID-19 therapies. , 2020, NPJ genomic medicine.

[9]  D. Siegel,et al.  Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study , 2020, The Lancet Rheumatology.

[10]  C. Gregoretti,et al.  Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review , 2020, Pulmonology.

[11]  Ansel Hoang,et al.  COVID-19 in 7780 pediatric patients: A systematic review , 2020, EClinicalMedicine.

[12]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[13]  M. Al-Jaghbeer,et al.  Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study , 2020, EClinicalMedicine.

[14]  Reza Gharebaghi MD MPH FAAO PhDc,et al.  Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen , 2020, The Journal of Antibiotics.

[15]  D. Kontoyiannis,et al.  Doxycycline as a potential partner of COVID-19 therapies , 2020, IDCases.

[16]  A. Bhagavathula,et al.  COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates , 2020, Cureus.

[17]  K. Samii,et al.  COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency , 2020, European journal of haematology.

[18]  Binqing Fu,et al.  Why tocilizumab could be an effective treatment for severe COVID-19? , 2020, Journal of Translational Medicine.

[19]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[20]  N. Chaput,et al.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report , 2020, Annals of Oncology.

[21]  E. Bosdure,et al.  COVID-19 virus and children: What do we know? , 2020, Archives de Pédiatrie.

[22]  F. Diekmann,et al.  Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? , 2020, American Journal of Transplantation.

[23]  Amirhossein Takian,et al.  COVID-19 battle during the toughest sanctions against Iran , 2020, The Lancet.

[24]  Gianpaolo Ronconi,et al.  Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. , 2020 .

[25]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[26]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[27]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[28]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[29]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[30]  N. Vickers,et al.  Animal Communication: When I’m Calling You, Will You Answer Too? , 2017, Current Biology.

[31]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[32]  T. Fredeking,et al.  Doxycycline modify the cytokine storm in patients with dengue and dengue hemorrhagic fever , 2010 .

[33]  A. Peters,et al.  Glucose-6-phosphate Dehydrogenase Deficiency and Malaria: Cytochemical Detection of Heterozygous G6PD Deficiency in Women , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[34]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[35]  B. Migeon,et al.  Localization of loci for hypoxanthine phosphoribosyltransferase and glucose-6-phosphate dehydrogenase and biochemical evidence of nonrandom X chromosome expression from studies of a human X-autosome translocation. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Chasin,et al.  Isolation of mammalian cell mutants deficient in glucose-6-phosphate dehydrogenase activity: linkage to hypoxanthine phosphoribosyl transferase. , 1975, Proceedings of the National Academy of Sciences of the United States of America.